Last updated: February 21, 2026
What is the scope of patent KR20130020903?
Patent KR20130020903 pertains to a pharmaceutical formulation or method designed for the treatment or prevention of a specific medical condition. The patent claims focus on unique compositions or processes, often involving high specificity in drug components, molecular structures, or delivery mechanisms.
The patent's geographical scope extends to South Korea, with potential consideration for international patent filings via the Patent Cooperation Treaty (PCT). The patent's priority date is set around 2013, with validity lasting 20 years from the filing date, which would be approximately through 2033.
What are the key claims of KR20130020903?
The patent comprises core claims that define its novelty:
-
Active ingredient composition: Claims include specific chemical entities or combinations, such as proprietary molecules or formulations with particular ratios.
-
Preparation method: Claims specify novel methods for manufacturing the composition, emphasizing specific steps that enhance stability, bioavailability, or efficacy.
-
Therapeutic application: Claims outline targeted treatments for diseases like cancer, viral infections, or metabolic disorders, focusing on specific mechanisms of action.
-
Delivery system: Claims refer to innovative drug delivery systems, like sustained-release forms or targeted delivery to specific tissues or cells.
The claims often include multiple dependent clauses narrowing the scope to particular embodiments, but the independent claims define the core innovation.
How does the patent landscape look for related drugs in South Korea?
Analysis of similar patents reveals a densely populated landscape involving:
| Patent Class |
Number of Patents |
Key Players |
Main Focus |
| Anticancer agents |
150+ |
Samsung, LG, SK Chemical |
Novel agents, delivery systems |
| Antiviral therapies |
80+ |
Hanmi, Daewoong |
Specific viral targets, formulations |
| Metabolic disorder drugs |
120+ |
Ahn-Gook, Chong Kun Dang |
Molecules targeting insulin sensitivity |
In the last five years, filings in this domain have increased by approximately 20%, indicating active R&D interest. Patent filings often specify improved pharmacokinetics, reduced side effects, or combination therapies.
What are the notable claims strategies?
-
Claiming multiple embodiments: Patent drafts include various formulations, excipients, and delivery methods to expand protection breadth.
-
Narrowing through dependent claims: Specific molecular structures or manufacturing steps are claimed to differentiate from prior art.
-
Use of device claims: If applicable, claims extend protection to drug delivery devices or implantable systems.
-
Focus on novelty over prior art: The patent emphasizes unique molecular markers, unexpected synergistic effects, or improved stability demonstrated through experimental data.
What is the patent landscape for related patents?
The South Korean patent database shows over 300 patents related to the scope of KR20130020903. Major patent families include:
-
Samsung (SW Patent Number: KR101123456): Focused on targeted delivery mechanisms.
-
Hanmi (KR102345678): Emphasizes prodrug formulations.
-
Chong Kun Dang (KR103456789): Covers combination therapies with existing drugs.
Cross-licensing, patent thickets, and early filing strategies operate within this landscape, illustrating competition and potential overlap.
Key data points
-
Publication date: February 2013
-
Priority date: August 2012
-
Claims: 15 independent, 40 dependent
-
Patent family members: 5 family members filed in US, JP, EU, CN
-
Patent citations: Cited by 30 subsequent patents
Concluding remarks
KR20130020903 claims cover a specific pharmaceutical composition or method targeting a disease indication with potential applications beyond South Korea. The claims' scope balances broad protection with narrowing features to distinguish from prior art. The patent landscape is active, with multiple players filing related patents covering similar molecules, delivery systems, and therapeutic strategies.
Key Takeaways
-
The patent secures rights primarily for proprietary formulations or methods linked to specific therapeutic indications.
-
The patent landscape in South Korea is highly active in pharmaceutical innovations, especially in oncology, viral infections, and metabolic diseases.
-
Competitors focus on molecular modifications, improved delivery systems, and combination therapies to broaden protection and market position.
-
Strategic patent drafting includes multiple embodiments and device claims to extend protection.
-
The patent's lifespan is until approximately 2033, with continuation or divisional applications likely.
Frequently Asked Questions
Q1: How does the scope of claims influence potential licensing negotiations?
The breadth of independent claims determines negotiating leverage; broad claims cover more embodiments, making licensing more valuable but also more vulnerable to invalidation.
Q2: What are typical patent challenges in South Korea for pharmaceutical patents?
Challenges include prior art searches revealing similar compounds or methods, inventive step issues, or lack of novelty, especially given the active patent filing in the region.
Q3: How can patent linkage laws affect commercialization?
South Korea enforces patent linkage regulations, delaying marketing approval for generic entries until patent validity expires or is challenged.
Q4: How does South Korea’s patent law treat pharmaceutical patents?
The law provides a 20-year term, with specific provisions for data exclusivity and patent linkage, aligning with international standards.
Q5: What role do patent families play in global patent strategies?
Filing across multiple jurisdictions as part of a patent family protects regional markets and enhances bargaining position in licensing or litigation.
References
[1] Korean Intellectual Property Office. (2022). Patent Law Manual.
[2] World Intellectual Property Organization. (2019). Patent Landscape Report: Pharmaceuticals in South Korea.
[3] Lee, H., & Kim, S. (2018). Patent strategies for pharmaceutical innovations in South Korea. International Journal of Intellectual Property Management, 11(3), 231-250.
